Amylin Pharmaceuticals Outlines Succession Plan
From Bloomberg News
Amylin Pharmaceuticals Inc. said Daniel M. Bradbury would replace Ginger Graham as chief executive within a year as the company works to boost sales of its Byetta and Symlin diabetes treatments.
Bradbury, 45, also was named to the board of directors. Graham, 50, who is keeping her board seat, will work with Bradbury on the transition, said Alice Bahner, a spokeswoman for the San Diego-based company.
Bradbury started at Amylin 12 years ago and has served as chief operating officer since 2003.
